Conatus Pharmaceuticals


Conatus Pharmaceuticals (CNAT): Analyst Is Putting Pen to Paper to Determine the Impact of Emricasan’s Setback

Nothing can kill a drug maker’s stock price like a failed clinical trial. Just take a look at the disaster that’s befallen Conatus …

Conatus Pharmaceuticals (CNAT): Oppenheimer Advises Investors to Wait for the Next Catalyst

Today, Conatus Pharmaceuticals (NASDAQ:CNAT) share price took a hit on the announcement that the drug maker’s POLT-HCV-SVR proof-of-concept clinical trial, in liver transplant patients …

What Spooked Conatus Pharmaceuticals (CNAT) Investors This Evening

Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …

Conatus Pharmaceuticals Inc (CNAT): Analyst Looks Forward to “Large Catalysts” Lying Ahead

Oppenheimer’s Jay Olson is optimistic about CNAT’s upside potential with the forthcoming topline data from the Phase 2 POLT study.

Thursday Morning Insights: Merrimack Pharmaceuticals Inc (MACK), Conatus Pharmaceuticals Inc (CNAT), Cleveland Biolabs, Inc. (BCLI)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares jumped over 9% in pre market trading to $12.98 after its New Drug Application for MM-398 was accepted for …

Stock Update (NASDAQ:CNAT): Conatus Pharmaceuticals Inc Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company’s Phase 2b clinical trial of …

Company Update (NASDAQ:CNAT): Conatus Pharmaceuticals Inc Appoints Mason M. Yamashita as Vice President, Pharmacovigilance

Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced the appointment of …

Stock Update (NASDAQ:CNAT): Conatus Pharmaceuticals Inc Appoints Jean L. Chan as Vice President, Clinical Development

Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced the appointment of …

Company Update (NASDAQ:CNAT): Conatus Pharmaceuticals Inc Reports First Quarter 2015 Financial Results and Program Updates

Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results …

Company Update (NASDAQ:CNAT): Conatus Pharmaceuticals Inc to Present Three Emricasan Clinical Results Posters at EASL Meeting

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that three posters addressing clinical results with emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor, have been …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts